A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3

British Journal of Clinical Pharmacology

Volumn 83, Issue 8, 2017, Pages 1734-1744

  Berger, Rolf M F ^a   Gehin, Martine ^b   Beghetti, Maurice ^c,d   Ivy, Dunbar ^e   Kusic Pajic, Andjela ^b   Cornelisse, Peter ^b   Grill, Simon ^b   Bonnet, Damien ^f  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^e CHILDREN S HOSPITAL   (United States)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

paediatrics; pharmacokinetics; vascular disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOSENTAN; HEMOGLOBIN; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; SULFONAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHOPNEUMONIA; CHILD; CLINICAL OUTCOME; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPOSURE; FEMALE; GROUPS BY AGE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INTERRUPTION; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; INFANT; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; PROSPECTIVE STUDIES; SULFONAMIDES;

EID: 85016015043     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13267     Document Type: Article

References (26)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2016; 44: D1054–68.
2. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al. The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 2015; 172: 5744–5869.
3. Simonneau G, Gatzoulis M, Adatia I. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34–D41.
4. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655–1665.
5. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011; 37: 665–677.
6. Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, et al. FUTURE-2: results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol 2016; 202: 52–58.
7. Beghetti M, Berger RM. The challenges in paediatric pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 498–504.
8. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948–955.
9. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372–382.
10. Berger RM. Pulmonary hypertension: smaller kids, smaller steps. Lancet Respir Med 2014; 2: 348–350.
11. Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Paediatr Drugs 2013; 16: 43–65.
12. Tracleer® (bosentan). Summary of product characteristics, February 2016.
13. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119–1123.
14. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48–54.
15. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353–359.
16. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.
17. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089–1115.
18. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697–704.
19. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664–670.
20. Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011; 38: 70–77.
21. van Loon RL, Hoendermis ES, Duffels MG, Vonk-Noordegraaf A, Mulder BJ, Hillege HL, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007; 154: 776–782.
22. Dell D, Lausecker B, Hopfgartner G, van Giersbergen P, Dingemanse J. Evolving bioanalytical methods for the cardiovascular drug bosentan. Chromatographia 2002; 55 (Suppl): S115–S119.
23. Gehin M, Sidharta PN, Dingemanse J. Bosentan pharmacokinetics in pediatric patients with pulmonary arterial hypertension: comparison of dried blood spot and plasma analysis. Pharmacology 2016; 98: 111–114.
24. Gutierrez MM, Nicolas LB, Donazzolo Y, Dingemanse J. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation. Int J Clin Pharmacol Ther 2013; 51: 529–536.
25. Ivy D, Abman SH, Barst RJ. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013; 62: D117–D126.
26. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125: 324–334.